- Home
- IXHL vs ZURA Comparison
IXHL vs ZURA Comparison
Compare IXHL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- ZURA
- Stock Information
- Founded
- IXHL 2001
- ZURA 2022
- Country
- IXHL Australia
- ZURA United States
- Employees
- IXHL N/A
- ZURA N/A
- Industry
- IXHL
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IXHL
- ZURA Health Care
- Exchange
- IXHL Nasdaq
- ZURA Nasdaq
- Market Cap
- IXHL 78.7M
- ZURA 69.9M
- IPO Year
- IXHL N/A
- ZURA N/A
- Fundamental
- Price
- IXHL $0.38
- ZURA $1.66
- Analyst Decision
- IXHL
- ZURA Strong Buy
- Analyst Count
- IXHL 0
- ZURA 9
- Target Price
- IXHL N/A
- ZURA $14.00
- AVG Volume (30 Days)
- IXHL 178.1M
- ZURA 369.7K
- Earning Date
- IXHL 09-29-2025
- ZURA 08-14-2025
- Dividend Yield
- IXHL N/A
- ZURA N/A
- EPS Growth
- IXHL N/A
- ZURA N/A
- EPS
- IXHL N/A
- ZURA N/A
- Revenue
- IXHL $98,000.00
- ZURA N/A
- Revenue This Year
- IXHL $2,538.49
- ZURA N/A
- Revenue Next Year
- IXHL $249.95
- ZURA N/A
- P/E Ratio
- IXHL N/A
- ZURA N/A
- Revenue Growth
- IXHL N/A
- ZURA N/A
- 52 Week Low
- IXHL $0.08
- ZURA $0.97
- 52 Week High
- IXHL $3.12
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- IXHL 44.52
- ZURA 58.91
- Support Level
- IXHL $0.34
- ZURA $1.44
- Resistance Level
- IXHL $0.57
- ZURA $1.52
- Average True Range (ATR)
- IXHL 0.13
- ZURA 0.13
- MACD
- IXHL -0.05
- ZURA 0.00
- Stochastic Oscillator
- IXHL 4.09
- ZURA 76.92
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.